Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0CWPX)

Drug Name
N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide Drug Info
Synonyms
N-(1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide; 301675-24-1; CHEMBL210658; N-(1H-benzimidazol-2-yl)-3-nitrobenzamide; AC1MTB3N; Cambridge id 7283005; Oprea1_384876; Oprea1_144350; MLS000418401; SCHEMBL3597174; MolPort-007-653-805; QPKROMNIEAEFQA-UHFFFAOYSA-N; MolPort-001-543-036; ZINC5033955; CS-M1436; STK433528; BDBM50184701; AKOS001825502; AKOS001141441; MCULE-1403873826; KB-78995; SMR000264931; CS-13909; ST50927847; N-benzimidazol-2-yl(3-nitrophenyl)carboxamide; 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
3572750
TTD Drug ID
DM0CWPX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting IRAK4 messenger RNA (IRAK4 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ISIS 156452 DMCU6RF Discovery agent N.A. Investigative [2]
ISIS 156453 DMQ9018 Discovery agent N.A. Investigative [2]
ISIS 156451 DMPH2W7 Discovery agent N.A. Investigative [2]
ISIS 156473 DMDFUS8 Discovery agent N.A. Investigative [2]
ISIS 156449 DMPB3FH Discovery agent N.A. Investigative [2]
ISIS 156474 DMCXP9T Discovery agent N.A. Investigative [2]
ISIS 156475 DMNB4UJ Discovery agent N.A. Investigative [2]
N-(1H-benzo[d]imidazol-2-yl)-3-cyanobenzamide DM054NF Discovery agent N.A. Investigative [1]
ISIS 156472 DM3U0Z6 Discovery agent N.A. Investigative [2]
ISIS 156471 DMM9ARP Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
IRAK4 messenger RNA (IRAK4 mRNA) TTILUKB IRAK4_HUMAN Inhibitor [1]

References

1 Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4. Bioorg Med Chem Lett. 2006 Jun 1;16(11):2842-5.
2 US patent application no. 6,692,959, Antisense modulation of IL-1 receptor-associated kinase-4 expression.